BioHarvest Sciences Inc. Appoints Nathaniel Averill as VP of Manufacturing, QA & Supply Chain
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2020) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") announces the appointment of Nathaniel Averill as Vice-President of Manufacturing, Quality Assurance and Supply Chain. This appointment has been made to support the Company Growth Strategy recently outlined by CEO, Mr. Ilan Sobel, supporting the expansion of its manufacturing capabilities and distribution of VINIA® and its pipeline of nutraceutical products and future Cannabis products into North America and other prioritized geographies. Mr. Averill will be based in Boston and will report directly to Mr. Ilan Sobel, the CEO.
Nathaniel Averill has over 25 years of experience in biotech pharmaceutical manufacturing. His expertise includes design, startup, and management of biotech facilities with companies such as Abbott Bioresearch Center, MedImmune Inc., and Bristol-Myers Squib. He was instrumental in the development and production of a number of blockbuster drugs including HUMIRA® (Adalimumab) and ORENCIA® (abatacept). Nathaniel also has expertise in remediation of compliance risks to approval of Federal Drug Administration (FDA), European Medicines Agency (EMEA), and other regulatory agencies.
When Massachusetts legalized medical marijuana in 2012, Nathaniel co-founded Healthy Pharms Inc. to produce medical marijuana under good manufacturing practice (GMPs) guidelines., which included a large cannabis growth facility, extraction operation, and dispensary. Nathaniel successfully sold Healthy Pharms Inc., to 4Front Advisors (a multi-state cannabis company) in 2016.
Mr. Averill will partner with Dr. Hagay (the CTO) and the key executives at Sugart Israel (BHSC's local manufacturing partner) in the set up and development of new 20 Tons per annum manufacturing facility which will produce VINIA® according to required US GMP specifications by early Q3, 2021. Mr. Averill will lead the local QA team in ensuring that BHSC and its manufacturing partners continue to uphold the highest levels of Quality Assurance across the industry and will lead the Supply Chain side of the business to maximize efficiencies and economies of scale.
In Boston, Mr. Averill will also be responsible for setting up a facility for BHSC to provide a North American showcase of our unique BioFarming capabilities. After gaining all appropriate local state licenses, he will be responsible for the conversion of this facility to a fully operating cannabinoid producing facility in 2022 serving the Massachusetts state market.
"It is a unique privilege to welcome Nathaniel to our team. It is a strong vote of confidence in BHSC's technology and prospects when an executive of such caliber joins the team," said Ilan Sobel, adding, "his wealth of experience in the most demanding industries in terms of capacity and quality will help us execute on our growth strategy and achieve our core values of customer satisfaction and quality. His multi-disciplinary expertise in manufacturing, Quality Assurance, and supply chain will enhance our ability to leverage our Biofarming technology to most economically produce the highest quality, most consistent, Nutraceuticals and cannabinoids. The timing of Nathaniel's arrival at BHSC could not be better as we see demand growing for our products in both B2B and B2C channels."
About BioHarvest Sciences Inc.
Based in Vancouver, BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.
BioHarvest Sciences Inc.
Chief Executive Officer
For further information, please contact:
VP Investor Relations & Director
Phone: 1 (604) 622-1186
Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance that we will achieve our objective of making our products available in multiple markets and exposing our technology to different verticals. There is no assurance the Company will obtain the necessary licenses to open a cannabinoid producing facility in Massachusetts or that such facility can be operating by 2022. There is no assurance that we will be able to sell our products to the pharmaceutical industry. There is also no assurance the Company will generate significant revenue in global nutraceutical and dietary supplements markets. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.
All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68150